Clinical trial

Thoracic Radiotherapy Plus EGFR-TKI for Stage III EGFR-mutant Lung Adenocarcinoma

NCT07857694

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

RADIATION · Unmapped registry intervention Thoracic radiotherapy Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention EGFR-TKI Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Thoracic Radiotherapy Plus EGFR-TKI for Stage III EGFR-mutant Lung Adenocarcinoma

Design: OBSERVATIONAL · Status: COMPLETED · Phase: Not specified

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeOBSERVATIONAL

Start date2020-01-01

PhaseN/A

Conditions

Lung Cancer Stage IIIunresolved

EGFR Activating Mutationunresolved

Interventions

Thoracic radiotherapyRADIATION

EGFR-TKIDRUG

Sponsors & collaborators

Laibin People's Hospitallead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07857694 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.